3 No-Brainer Dividend Stocks to Buy Right Now

AbbVie reported roughly $12.1 billion in third‑quarter revenue with immunology drugs Skyrizi and Rinvoq contributing about $4.1 billion and $1.56 billion respectively, and management projecting Skyrizi and Rinvoq could reach ~$17 billion and $10 billion in annual sales by 2027; the stock is up ~30% in 2025 and yields ~3%. Realty Income (O) owns over 15,500 properties, pays a monthly dividend (5.7% yield), and has raised its monthly payout 133 times since IPO, reflecting REIT payout requirements (~90% of profits). JPMorgan’s JEPQ ETF uses covered‑call equity‑linked notes on the Nasdaq‑100, yielding ~10.1% with a 3.6% YTD share gain and a 14.2% total return YTD (expense ratio 0.35%).

Analysis

Market structure: Winners are large cash-generator pharmas (ABBV) and high‑yield income vehicles (O, JEPQ). AbbVie’s Skyrizi/Rinvoq concentration drives outsized cashflow that increases buyback/dividend optionality through 2027 (management guideposts: Skyrizi $17B, Rinvoq $10B), while Realty Income’s diversified triple-net rent roll insulates short-term vacancy risk but remains rate‑sensitive. Covered‑call vehicles like JEPQ benefit yield‑hungry flows but cap upside for Nasdaq exposures.

Risk assessment: Tail risks include FDA/regulatory actions or patent losses (AbbVie) and a >100bp fast move up in 10‑yr yields that compresses REIT multiples and forces covenant stress for weaker tenants (Realty Income). Immediate (days) risks: earnings/guidance prints and option expiry flows; short term (weeks–months): trial readouts, litigation rulings, CPI/rate shocks; long term (quarters–years): patent cliffs, biosimilar uptake, secular retail footprint shifts. Hidden dependency: ABBV’s valuation and dividend resilience hinge on two products representing >40% of revenue; JEPQ yield sustainability breaks down if Nasdaq rallies >15% and option premia collapse.

Trade implications: Prefer barbell of income and idiosyncratic pharma exposure. Size ABBV exposure to 2–4% of portfolio with asymmetric hedges (6–9 month 10% OTM puts sized to 20–30% of notional) to protect from binary regulatory/legal outcomes; allocate 3–5% to O for steady income but cap position if 10‑yr >4.75%. Use JEPQ (1–3%) for locked yield if willing to forgo upside; alternate is QQQ + sell 1–2% OTM covered calls to avoid JEPQ fee drag.

Contrarian angles: Consensus underprices concentration risk at ABBV and overprices REIT stability if rates resume trending higher — both create mispricings. JEPQ’s 10% yield looks attractive but is distribution‑driven, not principal protection; in a tech selloff its NAV can decline >20% despite income. Historical parallel: big pharma with two blockbuster drugs often face rapid re‑rating on a single adverse readout (examples 2012–2016); position sizing and option hedges, not outright leverage, are the prudent plays.

Key Decisions for Investors

• Establish a 2–4% long position in ABBV (ticker ABBV) over the next 30 days, hedge with 6–9 month 10% OTM puts sized at ~25% of notional; add on pullbacks >10% from today’s price or after adverse headlines, trim if shares rally >20% from entry.
• Initiate a 3% core allocation to Realty Income (O) as a monthly‑income holding, increase to 5% only if AFFO payout ratio stays <95% and 10‑yr Treasury remains below 4.75%; set tactical stop/trim if 10‑yr >5.0% or same‑store NOI drops >3% QoQ.
• Buy JEPQ for 1–3% of portfolio as an income sleeve if cash yield priority >8%; alternatively execute QQQ + sell 1–2% OTM one‑month covered calls (roll monthly) to replicate income while avoiding JEPQ’s 0.35% fee drag if you expect Nasdaq upside.
• Pair trade: Long ABBV (2–4%) vs short biotech beta via IBB (size 50–70% of ABBV notional) to neutralize market beta while retaining idiosyncratic upside; unwind within 3–9 months around pipeline readouts or litigation rulings.